TY - JOUR T1 - Validated liquid chromatographic ultraviolet method for the quantitation of Etoricoxib in human plasma using liquid-liquid extraction. AU - Ramakrishna,N V S, AU - Vishwottam,K N, AU - Wishu,S, AU - Koteshwara,M, PY - 2004/08/23/received PY - 2004/11/17/accepted PY - 2005/1/25/pubmed PY - 2005/6/1/medline PY - 2005/1/25/entrez SP - 215 EP - 21 JF - Journal of chromatography. B, Analytical technologies in the biomedical and life sciences JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 816 IS - 1-2 N2 - A simple, sensitive and specific HPLC method with UV detection (284 nm) was developed and validated for quantitation of Etoricoxib in human plasma, the newest addition to the group of nonsteroidal anti-inflammatory drugs-a highly selective cyclooxygenase-2 inhibitor. Following a single-step liquid-liquid extraction with diethyl ether/dichloromethane (70/30, v/v), the analyte and internal standard (Zaleplon) were separated using an isocratic mobile phase of water/acetonitrile (58/42, v/v) on reverse phase Waters symmetry C(18) column. The lower limit of quantitation was 5 ng/mL, with a relative standard deviation of less than 20%. A linear range of 5-2500 ng/mL was established. This HPLC method was validated with between- and within-batch precision of 4.1-5.1% and 1.1-2.4%, respectively. The between- and within-batch bias was -3.8-4.7% and -0.6-9.4%, respectively. Frequently coadministered drugs did not interfere with the described methodology. Stability of Etoricoxib in plasma was >90%, with no evidence of degradation during sample processing (autosampler) and 30 days storage in a freezer. This validated method is sensitive and simple with between-batch precision of <6% and was used in pharmacokinetic studies. SN - 1570-0232 UR - https://www.unboundmedicine.com/medline/citation/15664353/Validated_liquid_chromatographic_ultraviolet_method_for_the_quantitation_of_Etoricoxib_in_human_plasma_using_liquid_liquid_extraction_ DB - PRIME DP - Unbound Medicine ER -